Alligator Bioscience AB (OSTO:ATORX) Total Liabilities : kr120.96 Mil (As of Jun. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Alligator Bioscience AB Total Liabilities?

Alligator Bioscience AB's Total Liabilities for the quarter that ended in Jun. 2025 was kr120.96 Mil.

Alligator Bioscience AB's quarterly Total Liabilities declined from Dec. 2024 (kr234.93 Mil) to Mar. 2025 (kr167.88 Mil) and declined from Mar. 2025 (kr167.88 Mil) to Jun. 2025 (kr120.96 Mil).

Alligator Bioscience AB's annual Total Liabilities increased from Dec. 2022 (kr80.53 Mil) to Dec. 2023 (kr106.60 Mil) and increased from Dec. 2023 (kr106.60 Mil) to Dec. 2024 (kr234.93 Mil).

Alligator Bioscience AB Total Liabilities Historical Data

The historical data trend for Alligator Bioscience AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alligator Bioscience AB Total Liabilities Chart

Alligator Bioscience AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

36.69

50.93

80.53

106.60

234.93

Alligator Bioscience AB Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25
Total Liabilities	Get a 7-Day Free Trial															130.07	167.78	234.93	167.88	120.96

Alligator Bioscience AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Alligator Bioscience AB's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	201.451	+	(33.475	+	-7.105427357601E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	234.93

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	104.338	-	-130.588
	=	234.93

Alligator Bioscience AB's Total Liabilities for the quarter that ended in Jun. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	91.035	+	(29.924	+	7.105427357601E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	120.96

Total Liabilities	=	Total Assets (Q: Jun. 2025 )	-	Total Equity (Q: Jun. 2025 )
	=	86.23	-	-34.729
	=	120.96

Alligator Bioscience AB Total Liabilities Related Terms

Thank you for viewing the detailed overview of Alligator Bioscience AB's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Alligator Bioscience AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alligator Bioscience AB (OSTO:ATORX) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

0RK9:UK 7AL0:Germany

Address

Medicon Village, Scheeletorget 1, Lund, SWE, 223 81

Website

https://www.alligatorbioscience.se

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. Its drug candidate mitazalimab, is currently in preparation for Phase 3 development, and has previously presented unprecedented survival data at 18-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1.

Alligator Bioscience AB Headlines

No Headlines